Vertex Pharmaceuticals Inc
NASDAQ:VRTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
392.81
516.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Vertex Pharmaceuticals Inc
Wall Street
Price Targets
VRTX Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
VRTX
is 516.02 USD
with a low forecast of 328.25 USD and a high forecast of 632.1 USD.
VRTX Last Price Targets
Vertex Pharmaceuticals Inc
The latest public price target was made on Nov 5, 2024 by
Hartaj Singh
from
Oppenheimer
,
who expects
VRTX
stock to
rise by 32%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Hartaj Singh
Oppenheimer
|
540
USD
Upside 32% |
1 month ago
Nov 5, 2024
|
Oppenheimer Reiterates Outperform Rating on Vertex (VRTX)
StreetInsider
|
Brian Abrahams
RBC Capital
|
451
USD
Upside 10% |
1 month ago
Nov 5, 2024
|
Vertex (VRTX) PT Raised to $451 at RBC Capital
StreetInsider
|
Whitney Ijem
Canaccord Genuity
|
361
USD
Downside 12% |
2 months ago
Oct 22, 2024
|
Canaccord Genuity Reiterates Sell Rating on Vertex (VRTX)
StreetInsider
|
Salveen Richter
Goldman Sachs
|
598
USD
Upside 46% |
2 months ago
Oct 21, 2024
|
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
StreetInsider
|
Evan David Seigerman
BMO Capital
|
566
USD
Upside 38% |
2 months ago
Oct 21, 2024
|
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
StreetInsider
|
Geoff Meacham
Bank of America Securities
|
541
USD
Upside 32% |
2 months ago
Oct 14, 2024
|
Vertex Pharmaceuticals price target lowered to $541 from $550 at BofA
TheFly
|
|
Brian Abrahams
RBC Capital
|
437
USD
Upside 6% |
2 months ago
Oct 9, 2024
|
Vertex Pharmaceuticals price target raised to $437 from $425 at RBC Capital
TheFly
|
|
Hartaj Singh
Oppenheimer
|
550
USD
Upside 34% |
4 months ago
Aug 5, 2024
|
Vertex (VRTX) PT Raised to $550 at Oppenheimer
StreetInsider
|
Joon Lee
Truist Financial
|
550
USD
Upside 34% |
4 months ago
Aug 5, 2024
|
Vertex Pharmaceuticals price target raised to $550 from $508 at Truist
TheFly
|
Andy Chen
Wolfe Research
|
576
USD
Upside 40% |
4 months ago
Aug 5, 2024
|
Vertex (VRTX) PT Raised to $576 at Wolfe Research
StreetInsider
|
|
Andrew Fein
H.C. Wainwright
|
600
USD
Upside 46% |
4 months ago
Aug 2, 2024
|
Vertex Pharmaceuticals price target raised to $600 from $500 at H.C. Wainwright
TheFly
|
Jasper Hellweg
Argus Research
|
550
USD
Upside 34% |
6 months ago
Jun 17, 2024
|
Vertex Pharmaceuticals price target raised to $550 from $465 at Argus
TheFly
|
|
Brian Abrahams
RBC Capital
|
421
USD
Upside 3% |
6 months ago
Jun 11, 2024
|
Vertex (VRTX) PT Lowered to $421 at RBC Capital
StreetInsider
|
|
Evan David Seigerman
BMO Capital
|
500
USD
Upside 22% |
6 months ago
May 31, 2024
|
Vertex (VRTX) PT Raised to $500 at BMO Capital
StreetInsider
|
Christopher Raymond
Raymond James
|
456
USD
Upside 11% |
7 months ago
May 7, 2024
|
Vertex (VRTX) PT Raised to $456 at Piper Sandler
StreetInsider
|
|
Brian Abrahams
RBC Capital
|
424
USD
Upside 3% |
7 months ago
May 7, 2024
|
Vertex (VRTX) PT Raised to $424 at RBC Capital
StreetInsider
|
Liisa Bayko
Evercore ISI
|
438
USD
Upside 7% |
8 months ago
Apr 11, 2024
|
Evercore ISI Upgrades Vertex (VRTX) to Outperform
StreetInsider
|
|
Andrew Fein
H.C. Wainwright
|
462
USD
Upside 13% |
8 months ago
Apr 11, 2024
|
Vertex Pharmaceuticals price target raised to $462 from $457 at H.C. Wainwright
TheFly
|
Unknown Analyst
Morgan Stanley
|
285
USD
Downside 31% |
1 year ago
Feb 8, 2023
|
Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $285
Benzinga
|
|
Unknown Analyst
H.C. Wainwright
|
326
USD
Downside 21% |
1 year ago
Feb 8, 2023
|
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $326
Benzinga
|
|
Unknown Analyst
Leerink Partners
|
365
USD
Downside 11% |
1 year ago
Feb 8, 2023
|
SVB Leerink Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $365
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VRTX's stock price target?
Price Target
516.02
USD
According to Wall Street analysts, the average 1-year price target for
VRTX
is 516.02 USD
with a low forecast of 328.25 USD and a high forecast of 632.1 USD.
What is Vertex Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
10%
For the last 8 years the
compound annual growth rate for
Vertex Pharmaceuticals Inc's revenue is
33%.
The projected
CAGR
for the next 4 years is
10%.
What is Vertex Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
13%
The
compound annual growth rate
of Vertex Pharmaceuticals Inc's operating income for the next 4 years is
13%.
What is Vertex Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
14%
The
compound annual growth rate
of Vertex Pharmaceuticals Inc's net income for the next 4 years is
14%.
You don't have any saved screeners yet
